Edwards Lifesciences (EW) Income from Continuing Operations (2009 - 2026)

Edwards Lifesciences' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 380700000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 4.7% year-over-year to 380700000.0 in Q1 2026; TTM through Mar 2026 was 1073100000.0, a 25.2% decrease from a year earlier, with the FY2025 full-year figure at 1056000000.0, down 24.36% from the prior year.
• Income from Continuing Operations advanced to 380700000.0 in Q1 2026 per EW's latest filing, from 64200000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 406400000.0 in Q2 2022 and bottomed at 64200000.0 in Q4 2025.
• The 5-year median for Income from Continuing Operations is 340500000.0 (2023), against an average of 318788235.29.
• Across the five-year window, Income from Continuing Operations soared 66.13% in 2023 and tumbled 81.39% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 200500000.0 in 2022, then surged by 66.13% to 333100000.0 in 2023, then grew by 3.57% to 345000000.0 in 2024, then tumbled by 81.39% to 64200000.0 in 2025, then jumped by 492.99% to 380700000.0 in 2026.
• Per Business Quant, the three latest EW Income from Continuing Operations figures stand at 380700000.0 (Q1 2026), 64200000.0 (Q4 2025), and 292300000.0 (Q3 2025).